On Apr. 13, 2020, Pluristem Therapeutics announced it has treated its first patient suffering from COVID-19 complications in the U.S. under the FDA Single Patient Expanded Access Program. The patient was treated with PLX cell therapy at Holy Name Medical Center in New Jersey, an acute care facility that is an active site for Pluristemﾒs Phase III critical limb ischemia study.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large scale quantities.